OVERVIEW

CJC‑1295 (no DAC) + GHRP‑6 10 mg (Blend) is a combination of two research peptides that has been studied in laboratory and preclinical settings for its effects on the growth hormone (GH) axis. CJC‑1295 (no DAC) is a synthetic analog of growth hormone‑releasing hormone (GHRH) designed to stimulate the anterior pituitary gland to release GH. Unlike versions of CJC‑1295 with a “drug affinity complex” (DAC), the no‑DAC form has a shorter half‑life, leading to pulsatile stimulation of GH release that more closely resembles natural physiological patterns. GHRP‑6 is a synthetic growth hormone‑releasing peptide that binds to the growth hormone secretagogue receptor (GHS‑R1a) — commonly known as the ghrelin receptor — to further stimulate GH secretion. When administered together in a blend, these peptides engage distinct but complementary pathways, potentially enhancing GH release more effectively than either peptide alone in experimental models. Researchers use such combinations to study the dynamics of GH regulation, metabolic signaling, and tissue responses in controlled laboratory environments.

Despite interest in this peptide blend, CJC‑1295 (no DAC) and GHRP‑6 are not approved by the U.S. Food and Drug Administration for therapeutic use in humans. Evidence supporting benefits in humans is limited, and most available data comes from laboratory or animal studies rather than large controlled clinical trials. Products marketed with this blend are typically labeled for research purposes only, meaning their purity, dosing accuracy, and safety standards are not regulated to pharmaceutical levels. Because of inconsistent quality and unknown long‑term effects, self‑administration outside of authorized research settings carries significant safety and ethical concerns. Anyone considering interventions related to hormone regulation should consult qualified healthcare professionals and rely on evidence‑based medical guidance rather than unregulated peptide compounds.